Oculis Announces Topline Results From Its Phase 2b RELIEF Trial With Licaminlimab, A Novel Anti-Tnfα Biologic Eye Drop

Author: Benzinga Newsdesk | June 10, 2024 05:13am

• Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trial
• Rapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43
• Licaminlimab was well tolerated similar to vehicle
• Company plans to finalize Phase 3 development plans following an End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA)

Posted In: OCS